STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY

Recruiting now

Conditions studied: Malignacy, Hemoglobinopathie

In brief

The Trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are more frequent in patients with hemoglobinopathies. Still, in relation to tumor pathology, the study will evaluate any differences between the different types of hemoglobinopathy and will investigate the association between the appearance of neoplasms and risk factors such as age, sex, iron accumulation markers, history of bone marrow transplant, and others.

Key facts

Study ID

NCT05286138

Run by

Società Italiana Talassemie ed Emoglobinopatie

People needed

10000

Starts

2022-02-01

Expected to finish

2052-02-28

Last updated by the study team

2022-04-01

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Transfusion-dependent or independent beta-thalassemia, hemoglobin H disease, sickle cell anemia and microdrepanocytosis
• Current or previous malignant tumor pathology
• Availability of medical history including the most relevant clinical and instrumental data before the onset of cancer

You may not qualify if…

• - Other haematological diseases other than hemoglobinopathies
• Absence of neoplastic events in the clinical history
• Non-availability of relevant clinical and instrumental data

Where it is running

• Azienda Ospedaliera Universitaria Di Cagliari — Cagliari, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.